



The Foundation, which began in 1995 as a grass roots effort, is now the global leader in the fight against Lymphangioleiomyomatosis (LAM). LAM is a rare and progressive lung disease that primarily affects women.

Through the efforts of a visionary Board of Directors, dedicated clinical and scientific leadership and an energetic staff, The LAM Foundation has raised and invested nearly \$25 million into research, patient support and clinical excellence. The research effort has produced over 125 grant-related publications, a diagnostic biomarker that can obviate the need for lung biopsy, clinical trials that identified the first FDA-approved treatment and a roster of active clinical trials seeking new and improved therapies. In addition to its world-renowned 30-member Scientific Board, the Foundation has assembled global LAM & Rare Lung Diseases Clinic and Research Network. There are 33 healthcare institutions in the United States and 25 globally that have assembled multi-disciplinary care teams with expert knowledge of LAM and clinical trial resources. This 'distributed expertise' model fosters scientific interest in LAM at academic medical centers around the world and provides care closer to home for patients. The annual International LAM Research Conference has been jointly sponsored by the NHLBI for 20 years brings together more than 400 LAM patients, family members, clinicians and investigators to focus all efforts on finding new treatments, improving quality of life and ultimately curing LAM in the shortest time frame. The Foundation provides a vital link to patients diagnosed with LAM, hosting a registry of 2,200 known patients and collaborating with sister LAM patient advocacy groups around the world through the Worldwide LAM Patient Coalition. Through a robust service line of patient communications, referrals, educational meetings and online support, The LAM Foundation connects patients and families who might otherwise never meet another person with a LAM diagnosis.

The LAM Foundation's goals are focused on targeted scientific development to include the new biomarkers to diagnose and predict disease progression, the identification of new drugs as possible treatments and driving the completion of all related clinical trials. Goals also include improved access to expert patient care, improving quality of life while living with LAM, increased global outreach to patients and scientists, and increased fundraising to support the needs of promising research and an ultimate cure.

The LAM Foundation Mission

The LAM Foundation urgently seeks safe and effective treatments, and ultimately a cure, for lymphangioleiomyomatosis (LAM) through advocacy and the funding of promising research. We are dedicated to serving the scientific, medical and patient communities by offering information, resources and a worldwide network of hope and support.